Sinopharm, an experimental coronavirus vaccine that was developed by China National Pharmaceutical Group, has showcased 86% efficacy. It was reported by Reuters, citing the Health Ministry of the United Arab Emirates.
It is worth noting that neither the UAE nor Sinopharm have released detailed data from their pivotal study.
UAE initiated Phase III clinical trials of this vaccine back in July. Two months later, the country authorized the emergency use of the vaccine for certain groups of the population.
"The analysis also shows 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease," the ministry said in a statement.
As we reported earlier, the Russian Ministry of Health has fixed the maximum cost price of its coronavirus vaccine, Sputnik V, at 26.20 dollars (1,942 rubles) for two doses.
"Russia’s Health Ministry has registered the maximum cost price of a producer for the vaccine to prevent novel coronavirus infection - Sputnik V, which was developed by the Gamaleya National Research Center for Epidemiology and Microbiology. It is 1,942 rubles for two doses," reads the message.